Empowering Cancer Therapy: Comparing PEGylated and Non-PEGylated Niosomes Loaded with Curcumin and Doxorubicin on MCF-7 Cell Line

Basit Öğe Kaydı
dc.authoridZarepour, Atefeh/0000-0002-0347-5840
dc.authoridZarrabi, Ali/0000-0003-0391-1769
dc.authoridSaharkhiz, Shaghayegh/0009-0001-3377-2934
dc.authorwosidZarepour, Atefeh/AAH-9225-2020
dc.authorwosidZarrabi, Ali/U-2602-2019
dc.contributor.authorSaharkhiz, Shaghayegh
dc.contributor.authorZarepour, Atefeh
dc.contributor.authorZarrabi, Ali
dc.date.accessioned2024-05-19T14:39:48Z
dc.date.available2024-05-19T14:39:48Z
dc.date.issued2023
dc.departmentİstinye Üniversitesien_US
dc.description.abstractCancer remains an enduring challenge in modern society, prompting relentless pursuits to confront its complexities. However, resistance often emerges against conventional treatments, driven by their inherent limitations such as adverse effects and limited solubility. Herein, we spotlight a remarkable solution; a niosomal platform engineered to tandemly ferry two potent agents, doxorubicin (DOX) and curcumin (CUR). Notably, we delve into the pivotal role of PEGylation, unraveling its impact on therapeutic efficacy. These niosomes consist of Span 60, Tween 60, and cholesterol with a molar ratio of 5:2:3, which were prepared via a thin film hydration method. The physicochemical characterization of particles was performed using DLS, zeta potential measurement, SEM, and FTIR analysis. In addition, their encapsulation efficiency and release profile were determined using the HPLC method. Finally, their cytotoxicity and biocompatibility effects were checked by performing an MTT assay test on the MCF7 and L929 cell lines. The obtained results confirmed the successful fabrication of co-loaded niosomal structures with and without PEG coating. The fabricated nanoparticles had sizes in the range of 100 to 200 nm with a surface charge of about -18 mV for particles without PEG coating and -40 mV for coated particles. Notably, DOX encapsulation efficiency leaps from 20% to 62% in the transition from uncoated to coated, while CUR exhibits an impressive surge from 80% to 95%. The drug release was more controlled and slower in the coated sample. Finally, the MTT results confirmed the biocompatibility and synergistic effect of the simultaneous use of two drugs on cancer cells in the PEGylated niosomal particle. Based on the results, PEGylated niosomal particles can be considered adept vehicles for the simultaneous delivery of different chemotherapy cargoes with synergic interaction to overcome cancer.en_US
dc.identifier.doi10.3390/bioengineering10101159
dc.identifier.issn2306-5354
dc.identifier.issue10en_US
dc.identifier.pmid37892889en_US
dc.identifier.scopus2-s2.0-85175241434en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org10.3390/bioengineering10101159
dc.identifier.urihttps://hdl.handle.net/20.500.12713/4850
dc.identifier.volume10en_US
dc.identifier.wosWOS:001096027000001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherMdpien_US
dc.relation.ispartofBioengineering-Baselen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240519_kaen_US
dc.subjectCanceren_US
dc.subjectCo-Loadingen_US
dc.subjectDrug Deliveryen_US
dc.subjectCurcuminen_US
dc.subjectDoxorubicinen_US
dc.subjectPegylationen_US
dc.titleEmpowering Cancer Therapy: Comparing PEGylated and Non-PEGylated Niosomes Loaded with Curcumin and Doxorubicin on MCF-7 Cell Lineen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu